Carbogen Amcis

Carbogen Amcis is a specialized Contract Development and Manufacturing Organization (CDMO) serving the global pharmaceutical and biopharmaceutical sectors. Established in 1982, the company has accumulated over four decades of technical expertise in drug substance and drug product development. They provide comprehensive commercialization services, supporting clients through the entire drug development lifecycle with rigorous regulatory compliance and high-quality manufacturing standards.

Operating with a workforce of 500-1,000 employees, Carbogen Amcis maintains a robust operational footprint across 8 global locations. The organization delivers scalable manufacturing solutions, including API production and complex formulation development. Their technical infrastructure supports diverse pharmaceutical requirements, ranging from small molecule synthesis to the production of specialized compounds. By leveraging advanced chromatography and GMP-certified processes, the company ensures consistent quality for both clinical and commercial-scale projects.

The firm distinguishes itself through deep technical proficiency in producing specialized compounds, including cholesterol and vitamin D analogs. With annual revenues reaching $202.5M, their service portfolio encompasses antibody-drug conjugates, peptide synthesis, and comprehensive pharmaceutical manufacturing support. As a key player in the B2B healthcare market, Carbogen Amcis focuses on delivering reliable outsourcing solutions that accelerate time-to-market for complex therapeutic products. Meet Carbogen Amcis's team to learn more about the leadership and technical experts driving these innovations. Their commitment to operational excellence and regulatory support remains central to their long-term strategy in the competitive pharmaceutical landscape.